Ann: BCAL to Host Analyst and Investor Webinar on 2 April 2025, page-4

Note - they said that the USA screening tests 40 years and over, and dense breast is in younger ages before menopause. ie, the revised lipid signature for dense breast, altered the sensitivity 91% / specificity 49%, and they said the full lipid signature would expect improved.

There are different market segments, the screening in AUS is over 50 y/o
But screening in USA is over 40 y/o
But there are younger people getting cancers who may need testing.

So they have breast test plus, cat d- to a signature for the younger dense breast